Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.

NCT01796171 is registered in ClinicalTrials.gov with Nordic Nanovector as lead sponsor.

NCT NCT01796171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01796171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.
Lead sponsor
Nordic Nanovector
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2012
Completion date
October 27, 2022
Enrollment
191 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, non-hodgkin lymphoma